Abstract
The effectiveness of chemotherapy in the treatment of many tumors is limited by two clinically distinct types of drug resistance. Tumors such as colon cancer, non-small lung cancer and malignant melanoma are inherently resistant to chemotherapy and response rates in these patients are low. In contrast, patients with tumors such as ovarian cancer and small cell lung cancer usually respond to the initial drug regimen but acquired drug resistance often develops and chemotherapy is of limited benefit in patients with recurrent or residual disease. A particularly clinically relevant feature of acquired drug resistance is the frequent development of a broad cross resistance to a wide variety of other drugs which is associated with the onset of resistance to the primary drug regimen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 455: 152–162, 1976.
Kartner N, Shales M, Riordan JR et al: Daunorubicinresistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res. 43: 4413–4419, 1983.
Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221: 1285–1288, 1983.
Beck WT, Mueller TJ, Tanzer LR: Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res. 39: 2070–2075, 1979.
Debenham PG, Kartner N, Siminovitch L et al: DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression. Mol. Cell. Biol. 2: 881–889, 1982.
Ling V: Genetic basis of drug resistance in mammalian cells. In: Drug and Hormone Resistance in Neoplasia, Vol. 1, Bruchovsky N, Goldie JH (eds), Miami, CRC, 1982, pp. 1–19.
Tsuruo T, Lida H, Yamashiro M et al: Enhancement of vincristine and adriamycin induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem. Pharm. 31: 3138–3140, 1982.
Tsuruo T: Reversal of acquired resistance to vinca alkaloids and anthrcyclines antibiotics. Cancer Treat. Rep. 67: 889–894, 1983.
Slater LM, Murray SL, Wetzel MW: Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J. Clin. Invest. 70: 1131–1134, 1982.
Tsuruo T, Iida H, Jojiri M et al: Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 43: 2905–2910, 1983.
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 42: 4730–4733, 1982.
Rogan AM, Hamilton TC, Young RC et al: Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994–996, 1984.
Bell DR, Gerlach JH, Kartner N et al: Detection of Pglycoprotein in ovarian cancer: A molecular marker associated with multidrug resistance. J. Clin. Oncol. 3: 311–315, 1985.
Meister A: New aspects of glutathione biochemistry and transport—selective alteration of glutathione metabolism. Nut. Rev. 42: 397–410, 1984.
Meister A: Selective modification of glutathione metabolism. Science 220: 472–477, 1983.
Arrick BA, Nathan CF: Glutathione metabolism as a determinant of therapeutic efficacy. A review. Cancer Res. 44: 4224–4232, 1984.
Biaglow JE, Varnes ME: The role of thiols in cellular response to radiation and drugs. Rad. Res. 95: 437–455, 1983.
Suzukake K, Petro BJ, Vistica DT: Reduction in glutathione content of L-PAM-resistant L1210 cells confers drug sensitivity. Biochem. Pharmacol. 31: 121–124, 1982.
Suzukake K, Vistica BP, Vistica DT: Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem. Pharmacol. 32: 165–167, 1983.
Relle-Somfai S, Suzukake K, Vistica BP, Vistica DT: Reduction in cellular glutathione by buthione sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem. Pharm. 33: 485–499, 1984.
Calcutt G, Connors TA: Tumor sulfhydryl levels and sensitivity to the nitrogen mustard merophan. Biochem. Pharmacol. 12: 839–845, 1963.
Gurtoo HL, Hipkens JH, Sharma CD: Role of glutathione in the metabolism-dependent toxicity and chemotherapy of cyclophosphamide. Cancer Res. 41: 3584–3591, 1981.
Griffith OW: Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. JBC 257: 13704–13712, 1982.
Griffith OW, Meister A: Potent and specific inhibitor of glutathione synthesis by buthionine sulfoximine (S-u-butyl homocysteine sulfoximine). JBC 253: 7558–7560, 1979.
Hamilton TC, Young RC, McKoy WM et al: Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43: 5379–5389, 1983.
Hamilton TC, Young RC, Ozols RF: Experimental model systems of ovarian cancer: Applications to the design and evaluation of new treatment approaches. Semin. Oncol. 11: 285–298, 1984.
Green JA, Vistica DT, Young RC et al: Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 44: 5427–5431, 1984.
Behrens BC, Louie KG, Hamilton TC et al: Resistance and cross resistance of human ovarian cancer cell lines to adriamycin, melphalan and irradiation. Proc. Amer. Assoc. Can. Res. 25: 336, 1984.
Hamilton TC, Young RC, Louie KG et al: Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis. Cancer Res. 44: 5286–5290, 1984.
Louie KG, Hamilton TC, Winker MA et al: Adriamycin accumulation and metabolism in adriamycin sensitive and resistant human ovarian cancer cell lines. Biochem. Pharmacol, (in press), 1985.
Hamilton TC, Winker MA, Louie KG et al: Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug resistant and sensitive human ovarian cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharmacol. 34: 2583–2586, 1985.
Hamilton TC, Young RC, Rogan AM et al: A unique intraperitoneal model of human ovarian cancer. Proc. Amer. Assoc. Can. Res. 25: 59, 1984.
Hamilton TC, Winker MA, Louie KG et al: Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity by buthionine sulfoximine depletion of glutathione in drug resistant human ovarian cancer cell lines. Proc. Amer. Assoc. Can. Res. 26: 345, 1985.
Wellner VP, Anderson ME, Puri RN et al: Radioprotection by glutathione ester: Transport of glutathione ester into human lymphoid cells and fibroblasts. Proc. Natl. Acad. Sci. USA 81: 4732–4735, 1984.
Myers CE: The biochemical basis for selective free radical injury. In: Rational Basis for Chemotherapy, New York, NY, Alan R. Liss, 1983, pp. 423–426.
Doroshow JH, Locker GY, Myers CE: Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J. Clin. Invest. 65: 128–135, 1980.
Ozols RF, Ostchega Y, Myers CE et al: High dose cisplatin in hypertonic saline in refractory ovarian cancer. J. Clin. Oncol, (in press), 1985.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Ozols, R.F., Hamilton, T.C., Louie, K.G., Behrens, B.C., Young, R.C. (1986). Glutathione Depletion with Buthionine Sulfoximine: Potential Clinical Applications. In: Valeriote, F.A., Baker, L.H. (eds) Biochemical Modulation of Anticancer Agents: Experimental and Clinical Approaches. Developments in Oncology, vol 47. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2331-0_13
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2331-0_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9432-0
Online ISBN: 978-1-4613-2331-0
eBook Packages: Springer Book Archive